Researchers find no increased risk of serious infection when comparing biologic and non-biologic psoriasis treatments
Researchers set out to determine whether three of the recommended biologic therapies (etanercept, adalimumab or ustekinumab) for psoriasis elevate the risk of serious infection above that for non-biologic, conventional tablet treatments.
Continue reading full article: Researchers find no increased risk of serious infection when comparing biologic and non-biologic psoriasis treatments